These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21983446)

  • 1. A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.
    Ruiz JF; Kedziora K; Keogh B; Maguire J; Reilly M; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6636-40. PubMed ID: 21983446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
    Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
    J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
    Marquez Ruiz JF; Kedziora K; Pigott M; Keogh B; Windle H; Gavin J; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1693-8. PubMed ID: 23416011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azo-reductase activated budesodine prodrugs for colon targeting.
    Marquez Ruiz JF; Kedziora K; O'Reilly M; Maguire J; Keogh B; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7573-7. PubMed ID: 23122819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
    Lee Y; Kim W; Hong S; Park H; Yum S; Yoon JH; Jung Y
    Eur J Pharmacol; 2014 Mar; 726():49-56. PubMed ID: 24462351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
    Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
    Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models.
    Ruiz JF; Kedziora K; Windle H; Kelleher DP; Gilmer JF
    J Pharm Pharmacol; 2011 Jun; 63(6):806-16. PubMed ID: 21585379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
    Li MH; Yin LL; Cai MJ; Zhang WY; Huang Y; Wang X; Zhu XZ; Shen JK
    Acta Pharmacol Sin; 2005 Jul; 26(7):865-72. PubMed ID: 15960895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.
    Malik P; Kadam RS; Cheruvu NP; Kompella UB
    Mol Pharm; 2012 Mar; 9(3):605-14. PubMed ID: 22256989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
    Bhardwaj A; Kaur J; Wuest F; Knaus EE
    ChemMedChem; 2014 Jan; 9(1):109-16, 240. PubMed ID: 24376205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation.
    Takashima-Hirano M; Takashima T; Katayama Y; Wada Y; Sugiyama Y; Watanabe Y; Doi H; Suzuki M
    Bioorg Med Chem; 2011 May; 19(9):2997-3004. PubMed ID: 21482120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
    Ghorab DM; Amin MM; Khowessah OM; Tadros MI
    Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
    Lee Y; Kim J; Kim W; Nam J; Jeong S; Lee S; Yoo JW; Kim MS; Jung Y
    Drug Des Devel Ther; 2015; 9():4105-13. PubMed ID: 26251576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eye pigmentation on transscleral drug delivery.
    Cheruvu NP; Amrite AC; Kompella UB
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression.
    Kuge Y; Katada Y; Shimonaka S; Temma T; Kimura H; Kiyono Y; Yokota C; Minematsu K; Seki K; Tamaki N; Ohkura K; Saji H
    Nucl Med Biol; 2006 Jan; 33(1):21-7. PubMed ID: 16459255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
    Lee Y; Kim J; Kim H; Kang S; Yoon JH; Kim DD; Kim YM; Jung Y
    J Pharm Sci; 2012 May; 101(5):1831-42. PubMed ID: 22334096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
    Jain SK; Gupta Y; Jain A; Bhola M
    Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
    Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
    Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.
    Nandy BC; Verma V; Dey S; Mazumder B
    Curr Drug Deliv; 2014; 11(5):621-35. PubMed ID: 24844925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.